Xenetic Biosciences (NASDAQ:XBIO) Trading Down 0.3% – Here’s What Happened

Xenetic Biosciences, Inc. (NASDAQ:XBIO)’s stock price fell 0.3% on Tuesday . The company traded as low as $3.00 and last traded at $3.08. 5,946 shares traded hands during mid-day trading, a decline of 57% from the average session volume of 13,713 shares. The stock had previously closed at $3.09.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenetic Biosciences in a research report on Monday, April 20th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.

Xenetic Biosciences Stock Performance

The company has a market capitalization of $7.05 million, a PE ratio of -2.57 and a beta of 2.19. The firm’s 50-day simple moving average is $3.11 and its 200 day simple moving average is $2.66.

Xenetic Biosciences (NASDAQ:XBIO) last issued its earnings results on Tuesday, May 12th. The company reported ($0.20) EPS for the quarter. The company had revenue of $0.81 million for the quarter. Xenetic Biosciences had a negative return on equity of 39.28% and a negative net margin of 70.03%.

Institutional Investors Weigh In On Xenetic Biosciences

A hedge fund recently raised its stake in Xenetic Biosciences stock. Renaissance Technologies LLC grew its stake in shares of Xenetic Biosciences, Inc. (NASDAQ:XBIO) by 516.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 178,509 shares of the company’s stock after purchasing an additional 149,559 shares during the period. Renaissance Technologies LLC owned approximately 7.80% of Xenetic Biosciences worth $387,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 15.12% of the company’s stock.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.